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Molecular imagingMetalloproteins have long been recognized as key determinants of endogenous contrast in magnetic
resonance imaging (MRI) of biological subjects. More recently, both natural and engineered metal-
loproteins have been harnessed as biotechnological tools to probe gene expression, enzyme activity,
and analyte concentrations by MRI. Metalloprotein MRI probes are paramagnetic and function by
analogous mechanisms to conventional gadolinium or iron oxide-based MRI contrast agents. Com-
pared with synthetic agents, metalloproteins typically offer worse sensitivity, but the possibilities of
using protein engineering and targeted gene expression approaches in conjunction with metallo-
protein contrast agents are powerful and sometimes deﬁnitive strengths. This review summarizes
theoretical and practical aspects of metalloprotein-based contrast agents, and discusses progress
in the exploitation of these proteins for molecular imaging applications.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Metalloproteins are essential to life. Roughly a third of proteins
are associated with metals, most frequently magnesium, zinc, iron,
and manganese, in order from most to least abundant [1]. Metallo-
prostheses enable many of these proteins to play important roles
in biological processes, prominently including photosynthesis, res-
piration, and various oxidation reduction reactions [2]. A particu-
larly impressive example, the cytochrome b6f from plants and
photosynthetic bacteria, contains four types of heme, a magnesiumporphyrin, and an [2Fe–2S] cluster all in a single supramolecular
assembly designed to drive proton gradient formation using en-
ergy from light absorbed by the metal complexes [3]. Both optical
and electronic properties of the metal centers thus contribute to a
reaction that ultimately gives rise to the nutrients used by most
organisms on the planet. A far simpler but also famously vital
metalloprotein is hemoglobin (Hb). Hb contains four polypeptides,
each bound to a heme group. Oxygen binding to the metal centers
induces a change in the coordination geometry, which in turn
drives a global conformation change that favors further oxygen
binding [3]. Via this mechanism, the chemistry of metal–ligand
interactions governs the ability of Hb to bind and release oxygen
in physiologically appropriate concentration ranges.
Biophysical properties of metalloproteins and protein–metal
interactions have led to a number of biotechnological applications.
The strength and speciﬁcity of metal chelation by polypeptides
gives rise to the well-known Ni2+ afﬁnity puriﬁcation method used
to isolate polyhistidine-tagged proteins [4]. Catalytic oxidation of
chlorinated alkanes by a diiron active center in methane monoox-
ygenase from Methylosinus trichosporium OB3b has been used for
bioremediation of contaminated groundwater [5,6]. A redox-active
metalloprotein, azurin, has been used as a biotransistor [7] and
component of a protein-based biomemory device [8]. Metallopro-
teins are also a basis for monitoring physiology in living animals.
The most famous example is provided again by Hb, which due to
the oxygen-dependent spectral properties of its heme groups,
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Fig. 1. Mechanisms of MRI contrast enhancement by paramagnetic metallopro-
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tially absorbed by oxy- and deoxy-Hb, is the basis for vital signs
monitoring in virtually every hospital in the world [9].
It has been recognized more recently that magnetic properties
of metalloproteins also provide important biotechnological capa-
bilities. Many metalloproteins contain ions with unpaired elec-
trons, rendering them paramagnetic and detectable or
manipulable by magnetic tools. Accompanying the excitement
around optogenetics [10] has been a particular interest in using
metalloproteins such as ferritin (Ft) to provide magnetic ‘‘handles’’
on cell function. In a recent example, implanted cells overexpress-
ing a Ft derivative were induced by application of oscillating mag-
netic ﬁelds to secrete insulin in mice [11]. There is also a
suggestion that protein-catalyzed paramagnetic metal accumula-
tion in cells could be used for magnetic pull-down assays [12,13].
Finally, paramagnetic metalloproteins have been used as contrast
agents for magnetic resonance imaging (MRI). Here, the prospect
of ﬁnding MRI-detectable analogs to green ﬂuorescent protein
(GFP) has been an important inspiration; a hope is that suitable
proteins could be used as gene reporters and sensors analogous
to the various ﬂuorescent and luminescent proteins that have
transformed research in cell biology over the past two decades.
Although the majority of MRI contrast agents have historically
been based on small organic molecules such as Gd3+ chelates
[14,15], metalloprotein MRI contrast agents present a variety of
advantages, each of which may be important in distinct contexts.
Thanks to the advancement of molecular biology techniques, pro-
teins are much easier to synthesize and modify than organic mol-
ecules; numerous protein engineering techniques may be applied
to tune metalloprotein properties for MRI (reviewed in [16]). Due
to their larger size, protein-based contrast agents are retained in
the blood pool for a longer time than small molecule agents, allow-
ing for longer imaging times in some types of experiments [17,18].
In some cases, metalloproteins can indeed be targeted and ex-
pressed using gene delivery methods, a la GFP [19,20]. Such report-
ers generate relatively static contrast, but can allow particular
types of cells to be tracked in vivo over time [21–23]. By further-
more sensitizing metalloprotein contrast agents to analytes
[24,25], additional information about physiologically relevant sig-
nals can be obtained. Development of such environmentally-sensi-
tive agents is underway but largely in its infancy. In this article, we
discuss the characteristics of metalloprotein-based MRI contrast
agents and review recent progress in the development and applica-
tions of magnetically active proteins in these new spheres of
investigation.teins. (A) Protein-based T1 contrast agents operate largely through an inner sphere
relaxation mechanism dependent on metal-coordinated water molecules in fast
exchange with bulk solvent. In the example shown (top), the heme iron (brown) of
an engineered P450 BM3 variant (gray ribbon structure) interacts with an axial
inner sphere water ligand (blue ball, arrowhead) [24]. Bound water protons (not
shown) experience dipole coupling with the metal ion and undergo relaxation. T1
Relaxivity of the complex may also be promoted by the presence of second sphere
water molecules (additional blue balls) that participate in weak dipole coupling
with the iron atom and exchange with water in the inner sphere position. The T1
contrast affects the saturation of MRI signals during repeated application of a pulse
sequence (schematics at bottom; pulses in gray and raw MRI signal in black). In the
absence of the contrast agent, the MRI signal tends to decline due to saturation over
time (top trace). The T1 agent relieves this effect (bottom trace), resulting in a
enhanced signal and relative hyperintensity in images. (B) The best-characterized
protein T2 contrast agent is ferritin (Ft, ribbon structure), a shell-shaped oligomer of
24 subunits (one shown in purple) that contains a paramagnetic hydrated iron
oxide core. The core induces a dipolar ﬁeld perturbation (ﬁeld lines shown) over a
length scale comparable to the core diameter, and water molecules (blue balls)
undergo transverse relaxation by diffusing through the dipole ﬁeld. The amplitude
of an MRI signal obtained using a T2-weighted pulse sequence (schematics at
bottom) depends on the amount of T2 relaxation that has occurred prior to
acquisition of the signal with each repetition of the pulse sequence. A T2 contrast
agent like Ft promotes T2 relaxation and leads to attenuation of the signal (bottom
trace) and relative hypointensity in MRI scans. Ft structural model from reference
[125].2. Theoretical basis of MRI contrast agents
In proton MRI [26], the form of MRI most commonly applied in
laboratories and clinics, populations of nuclear spins arising from
hydrogen nuclei primarily in water are perturbed and monitored
to generate images. At thermal equilibrium in a strong magnetic
ﬁeld (B0), the water proton spins align weakly with the applied
ﬁeld and give rise to a net ‘‘longitudinal’’ magnetization aligned
with B0. This magnetization is unobservable, but can be detected
following application of radiofrequency energy pulses which tilt
the magnetization vector off of the B0 axis and give rise to a non-
zero ‘‘transverse’’ magnetization component. After excitation, the
transverse magnetization component decays away with a time
constant T2 (the transverse relaxation time) and the overall magne-
tization returns to thermal equilibrium with a time constant T1
(the longitudinal relaxation time). The shorter T1 is, the more fre-
quently an MRI signal can be repeatedly measured per unit time;
areas of a specimen with short T1 therefore give rise to a larger
average MRI signal. Conversely, the shorter T2 is, the more rapidlythe observable component of magnetization disappears, and the
lower the MRI signal becomes.
Paramagnetic species inﬂuence contrast in MRI by reducing the
T1 and T2 relaxation times [27,28] (Fig. 1). In both cases, accelerated
relaxation arises from coupling between the magnetic dipole of the
contrast agent and the nuclear spins of water molecules that inter-
act with the agent through bonds (‘‘inner sphere’’ interactions) or
through space (‘‘outer sphere’’). Relaxation rates R1 (= 1/T1) and
R2 (= 1/T2) are generally linear with contrast agent concentration.
The slopes of these relationships are referred to as the T1 and T2
relaxivities, r1 and r2, respectively, which measure the strength of
the contrast agent and are expressed in units of mM1 s1. Greater
relaxivity is beneﬁcial to an MRI contrast agent, because the agent
can then be applied at lower doses or to greater effect at any given
concentration. Both r1 and r2 vary strongly with B0 and depend on
physical parameters including the electron spin number (S) or
magnetic moment of the contrast agent, the number of coordi-
nated inner sphere water molecules (q), the time constant for inner
sphere water exchange (sM), and the rotational correlation time of
the agent (sR). Inner sphere contributions to relaxivity are de-
scribed by the theory of Solomon, Bloembergen, and Morgan
[29–31], and apply to metalloproteins with adjustments to account
for slow rotation in macromolecules [32]. Outer sphere contribu-
tions are described by related theories applicable to mononuclear
[33] and particulate [34–36] metal complexes. Determinants of
relaxivity are summarized in the Appendix to this article, and are
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39]. Relaxivity determinants are important not only because they
explain how contrast agents may be optimized, but also because
they provide potential mechanisms for designing MRI-detectable
sensors.
Most MRI contrast agents or sensors, including paramagnetic
proteins, tend to affect T1-weighted MRI scans more than T2-
weighted scans, or vice versa, and are correspondingly referred to
as T1 or T2 agents. T1 agents have an r1/r2 ratio of 1 to 2 and gener-
ally contain one or a small number of paramagnetic ions. Classical
T1 agents are exempliﬁed by complexes of Gd3+ with small chela-
tors like diethylenetriaminepenaacetic acid (DTPA) [40,41], and
are the most commonly applied agents in clincial MRI; analogous
proteins can include porphyrin prostheses or directly bound metal
ions (Fig. 1A). At typical ﬁeld strengths for clinical or preclinical
MRI (>1 T), most T1 agents have r1 values from 1 to 10 mM1 s1.
In biological samples with T1 values typically near 1 s, T1 agents
need to be applied at concentrations near 100 lM to induce sub-
stantial contrast effects; 100 lM of a contrast agent with r1 -
= 5 mM1 s1, for instance, would induce an MRI signal increase
of 20% against a background with a T1 of 1 s under conditions
of optimal signal to noise ratio. Inner sphere r1 contributions are
usually particularly important for T1 agents, and T1-based sensors
typically undergo analyte-dependent changes in the parameters
that most affect inner sphere relaxation mechanisms, such as q
and sR.
T2 agents have r2/r1 ratio greater than 10 (a necessary condi-
tion because T2 values are much shorter than T1 values in vivo)
and are best exempliﬁed by superparamagnetic nanoparticles
(SPNs) [42–44], contrast agents that incorporate discrete crystal-
line domains that exhibit highly cooperative magnetic behavior.
A biosynthetic analog to SPNs is ferritin (Ft) [34], an iron storage
protein that accumulates minerals in a 12 nm shell like structure
formed from 24 polypeptide chains (Fig. 1B). SPN T2 agents pro-
duce high r2/r1 ratio because they become magnetized by the B0
ﬁeld and create microscopic magnetic perturbations experienced
by diffusing water molecules in solution. These perturbations af-
fect T2 relaxation more than T1, particularly for particles with
highly magnetic mineral cores over 3 nm in diameter and at high
B0 strengths (>1 T), where SPN magnetizations tend toward an
asymptotic ‘‘saturation’’ point [45]. The physics of the interaction
between diffusing protons and SPNs also leads to a strong depen-
dence of r2 on R2/D, where R is the mineral core radius and D is
the solvent self-diffusion constant (see Appendix); SPNs with lar-
ger size shorten T2 more effectively, up to a so-called static dephas-
ing limit [46] near 50 nm for typical SPNs. Most SPN contrast
agents incorporate iron oxide; synthetic iron-containing SPNs usu-
ally have r2 values of 50–500 (mM Fe)1 s1. Given typical back-
ground T2 values near 100 ms in tissue, synthetic SPNs applied at
concentrations of 1–10 lM Fe can produce substantial effects un-
der optimal T2-weighted imaging conditions. For instance, an agent
with r2 = 200 mM1 s1 could produce a 20% decrease in MRI sig-
nal at a concentration of 10 lM Fe. Because of the dependence of r2
on particle size for SPN agents, sensors can be constructed by cou-
pling analyte concentration to the clustering of these particles
[47,48], which results in de facto size changes [49].
3. Relaxivity of protein contrast agents
Protein contrast agents have distinct advantages and disadvan-
tages compared with conventional synthetic contrast agents in
terms of relaxivity. In most cases, proteins are handicapped by
incorporating metal ions with electronic properties that are subop-
timal for R1 or R2 enhancement [50]. Naturally-occurring paramag-
netic proteins tend to contain Cu2+, Mn2+, Mn3+, Fe2+, or Fe3+ ions,ranging in spin number from 1/2 to 5/2. On the other hand, Gd3+
ions used in most synthetic small molecule agents provide S = 7/
2. Since relaxivity values are approximately proportional to
S(S + 1), the maximum relaxivity of a gadolinium agent is about
twice what would be achieved in principle with a transition me-
tal-containing protein with otherwise equivalent relaxivity param-
eters. Electronic relaxation times T1e and T2e have a great inﬂuence
on inner sphere relaxivities and also tend to be less advantageous
(shorter) for transition metals than for gadolinium. Short electronic
relaxation times limit relaxivity when they are less than the molec-
ular motion timescale sR (10 ns), as has been reported for some
metalloproteins. A further limitation on the relaxivity of metallo-
proteins, compared with small metal complexes, can arise from
the relative inaccessibility of protein-coordinated metal ions to
outer sphere water molecules. At ﬁeld strengths above 1.5 T, outer
sphere interactions account for a sizeable fraction of the r1 of typ-
ical small molecule contrast agents [37,51], a contribution that
could be reduced due to steric effects in a macromolecule.
The limitations of metalloprotein contrast agents are partially
offset by properties that are predicted to beneﬁt relaxivity. At mod-
erate magnetic ﬁeld strengths and for molecules with sufﬁciently
long electronic relaxation times, inner sphere relaxivity tends to
be greater for molecules with longer sR [52]. Approximate sR values
can be estimated by the Stokes–Einstein relationship [53] and are
proportional to molecular size; values of 10 ns or above are typical
of proteins (>20 kDa), whereas small molecules generally have sR
less than 1 ns. Water structure around metalloproteins may also
be conducive to greater relaxivity. Many paramagnetic proteins
provide more than one water-accessible coordination site per me-
tal ion (q > 1), compared with q = 1 for conventional Gd3+-contain-
ing contrast agents; this is a substantial beneﬁt because inner
sphere relaxivity scales with q. Although complexes with higher
q bind metal ions less tightly, the potential health risk from com-
plex dissociation is mitigated by the fact that naturally abundant
transition metals are far less toxic than Gd3+ at low doses. The
presence of additional bound water molecules associated with
metalloproteins, including ‘‘second sphere’’ waters near but not di-
rectly coordinated to paramagnetic ions, may confer a further
relaxivity gain [54]. A ﬁnal relaxivity-related advantage of protein
contrast agents over some small molecule agents is their relative
solubility. Most cytosolic or secreted metalloproteins are evolved
to remain in solution or interact with well-deﬁned ligands; this
limits the potential for biological environments to substantially de-
grade relaxivity or analyte sensing capabilities by adversely affect-
ing water proton interaction parameters.
The preceding discussion of advantages and disadvantages re-
lates most directly to synthetic vs. metalloprotein T1 agents, but
analogous criteria differentiate synthetic T2 agents (SPNs) from Ft
as well. Synthetic iron oxide SPN contrast agents contain magnetite
or maghemite, magnetic materials with saturation magnetization
(MS) values of 92–100 or 60–80 emu/g, respectively [55], whereas
Ft naturally contains a hydrated iron oxide called ferrihydrite,
which has a reported MS of only 0.9–1.2 emu/g [56]. Because the
expected T2 effects of iron oxide cores are proportional to their
magnetization, the relaxivity of Ft at saturating B0 is in principle
only about 1% that of synthetic iron oxides for equivalent core
sizes. The situation with ferrihydrite-loaded Ft may be more com-
plex, however, as its r2 appears to increase linearly with ﬁeld at
least up to 11.7 T, as opposed to reaching a saturating value around
1 T like most SPNs [57]. Further, it has been shown that Ft r2 is
more directly dependent on stored iron concentration than on core
size per se [58], suggesting an important role for inner sphere
relaxivity mechanisms akin to those of conventional paramagnetic,
as opposed to superparamagnetic, contrast agents. Practical advan-
tages of Ft compared with synthetic SPNs include its regular struc-
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or engineering the relaxivity of Ft-based contrast agents.
4. Natural metalloproteins in MRI
The ﬁrst substantial investigation of magnetic properties in a
metalloprotein centered on hemoglobin, the oxygen transporting
heme protein in blood. Pauling and Coryell reported in a 1936 pa-
per that hemoglobin is paramagnetic in the absence of ligand but
diamagnetic when bound to oxygen [59]. This discovery eventually
led to the development of blood oxygenation level dependent
(BOLD) technique for functional neuroimaging (fMRI) studies
[60], which is by far the most commonly exploited example of
metalloprotein-induced contrast in MRI. In the BOLD effect, T2-re-
lated signal changes are produced by variations in the oxygenation
of hemoglobin in blood vessels. Although deoxyhemoglobin can act
as a contrast agent through direct interactions with water mole-
cules, its dominant contribution in the BOLD effect is to change
the overall magnetic susceptibility of erythrocytes and blood ves-
sels in their entirety, converting these structures into cellular-scale
‘‘contrast agents’’ that alter MRI signal by outer sphere effects anal-
ogous to those of SPN agents [61]. The BOLD effect is enabled by
the large concentration of hemoglobin, 150 g/L in whole blood
[62], giving rise to 4 mM Fe, which ensures that even a relatively
low percentage of deoxygenation translates into a formidable
deoxyhemoglobin concentration. In BOLD fMRI, brain activity-in-
duced increases in the blood supply to affected areas induces tran-
sient drops in the concentrations of deoxyhemoglobin, which are
detectable as localized MRI signal increases [63–65]. BOLD imaging
has been applied to detect hemodynamic changes in other tissues
as well [66,67], and a BOLD-like effect produced by paramagnetic
deoxymyoglobin in muscle can also be used to monitor aspects
of muscular physiology [68].
More recently, interest in exploiting natural metalloproteins for
MRI contrast has revolved largely around the potential for ex-
pressed paramagnetic proteins to act as gene reporters. An early ef-
fort to express myoglobin in transgenic mice did not produce
substantial MRI contrast changes [69], but contrast changes have
been achieved by overexpressing Ft in cells and animals. Ft has
been reported to bind up to 4500 Fe atoms per 24-mer [70], pro-
viding a stoichiometric advantage of over a hundred, compared
with heme proteins, in terms of sheer iron accumulation. Although
many of the iron atoms in Ft are organized into ‘‘antiferromag-
netic’’ ferrihydrite domains [71], the limited per-iron relaxivity of
Ft is still compensated for by the number of atoms that can be
stored. The effect of overexpressing Ft was ﬁrst demonstrated in
C6 glioma cells transfected with murine heavy chain Ft (one of
two isoforms, heavy and light, expressed in mammals) [72]. A
2005 study then showed for the ﬁrst time that ectopic (adenovirus
driven) Ft overexpression leads to detectable T2 contrast in rodent
brains [73], and later papers reported T2 effects in transgenic mice
[74] and transplanted cells in vivo [21–23].
A requirement for efﬁcacy of the Ft reporter approach is that
highly regulated endogenous iron dynamics must be effectively
perturbed by overexpression of the metalloprotein without toxic
effects on cells; this criterion might be satisﬁed to varying extents
in different tissues or cell types. Indeed, as potential gene report-
ers, metalloproteins in general are limited by the kinetics of metal
ion transport and processing. Iron uptake by cells, for instance, de-
pends on the import rate and availability of extracellular iron
sources, and can require exposure times on the order of hours to
achieve saturation [75–77]. To address the potentially restrictive
role of iron import machinery, one study proposed co-expressing
Ft with the transferrin receptor, a natural participant in cellular
iron transport [78]. A conceptually related strategy involves usingoverexpression of paramagnetic metal ion transporters themselves
to induce MRI contrast; contrast changes in rodents have been re-
ported using the magnetotactic bacterial protein MagA [79] and
the mammalian divalent cation transporter DMT1 [80], but it is
not clear which speciﬁc metalloproteins might be involved in bind-
ing the metal ions once they have entered cells.
5. Engineering protein-based contrast agents to detect
biological targets
One of the greatest strengths of protein contrast agents with re-
spect to small molecules is in the area of biomolecular target
detection, the objective of ‘‘molecular imaging.’’ The large surface
area and numerous functional groups presented by protein inter-
faces render these macromolecules especially suited to binding po-
tential ligands with high afﬁnity and speciﬁcity. Although the
potential utility of natural metalloproteins for MRI is far from fully
explored, however, it is unusual to be able to ﬁnd a naturally
occurring paramagnetic molecule that spontaneously ﬁts the de-
mands of a particular biosensing application. Here another
strength of proteins—their amenability to engineering ap-
proaches—comes into play. Whereas modifying small molecule
agents often requires complicated synthetic schemes, proteins
may be engineered using simple DNA-level changes or straightfor-
ward post-translational approaches [16].
The simplest examples of how proteins may be modiﬁed to
facilitate analyte detection include the use of bioconjugation strat-
egies to attach protein targeting domains to metal compounds, cre-
ating metal-protein hybrids with desirable binding and relaxivity
properties. This approach was ﬁrst applied to attach Gd3+ ions to
antibodies esteriﬁed to DTPA or similar chelating groups [81–83],
in the expectation that the resulting complexes could be used to
home in on antigens in vivo and facilitate their visualization by
MRI. A recent achievement using this type of approach involved
the modiﬁcation of the neuronal tract tracer cholera toxin subunit
B with Gd3+-tetraazacyclododecanetetraacetic acid (Gd-DOTA)
complexes [84]. The resulting molecules were injected into rat
brains, where they were taken up by neurons and transported to
distal areas connected to the injection site, exposing patterns of
connectivity in the brain. Protein bioconjugation strategies have
also been extensively applied in combination with SPNs, which
provide substantially greater contrast per metal atom than para-
magnetic T1 agents [36]. Individual SPN particles can be attached
to multiple targeting proteins, adding the potential for improved
targeting through avidity effects. SPN-protein conjugates have
been produced to target genetically-expressed reporters [85],
markers of apoptosis [86], vascular pathology [87], and cancer cells
[88,89]. Analyte sensors have also been actuated by proteins that
bring about reversible clustering of SPNs in the presence of various
targets [90,91]. In one instance, a calcium ion sensor was made by
attaching SPNs to two proteins that bind to each other in the pres-
ence but not the absence of Ca2+ [91]. Calcium-dependent SPN
aggregation was observed and response properties could be tuned
by further engineering of the protein domains.
Canonical metalloproteins have also been engineered to act as
MRI probes. Heme proteins are particularly attractive bases for
MRI sensors because of their high metal afﬁnity and diverse ligand
binding functionality, but their properties typically need to be ad-
justed. For instance, Hb is the quintessential metalloprotein-based
sensor [60], but its use as an explicit probe for measuring tissue
oxygen pressure (pO2) by MRI is hindered by the fact that its nat-
ural binding midpoint (EC50) is near a pO2 of 8 mmHg, below con-
centrations normally found in tissue. Crosslinking Hb with
glutaraldehyde improves its stability and shifts to the EC50 to
38 mmHg [92], allowing it to sense physiological relevant pO2 lev-
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generalizable example of heme protein engineering for MRI, a bac-
terial cytochrome P450 heme domain (BM3h) that normally binds
unsaturated fatty acids was retuned through the process of direc-
ted evolution [94] to bind and sense neural signaling molecules
[24] in which binding of the analytes competes with inner sphere
water to bring about a change in q (Fig. 2A). Over ﬁve rounds of
random mutagenesis and selection based on an optical titration
screen, BM3h variants were obtained with micromolar afﬁnity
for dopamine, a neurotransmitter involved in reward-related sig-
naling in the brain. These sensors had Dr1 of 1 mM1 s1 at
4.7 T (Fig. 2B), a modest change, but one that nevertheless permit-
ted detection of stimulus-induced dopamine release in rats. The
same directed evolution strategy could also be applied to generate
sensors for other targets, such as the neurotransmitter serotonin
[24].
Ft is an obvious platform for engineering MRI probes because of
its similarity to SPNs and the evidence that endogenous [95–97] or
ectopic [73,74] Ft expression affects MRI contrast in vivo. The most
natural way to engineer Ft without disrupting its metal storage
functionality is to ‘‘display’’ targeting moieties on the protein sur-
face. In one example of this approach, Uchida et al. introduced a tu-
mor targeting peptide, RGD-4C, at the N-terminus of human heavy
chain Ft and conﬁrmed that the engineered protein (RGD4C-Fn)
can still mineralize iron oxide in its cavity [98]. RGD4C-Fn was
shown to bind melanoma cells better than unmodiﬁed Ft. The sol-
vent exposed Ft N-terminus can also be modiﬁed to create respon-
sive MRI contrast agents. Following this strategy, Shapiro et al.
developed a protein kinase A (PKA) activity sensor based on Ft,
which produces aggregation-dependent T2-weighted MRI contrast
changes analogous to those obtained using synthetic SPNs [99].
The PKA sensor contains two populations of engineered Ft parti-
cles, one fused with the kinase inducible domain (KID) of the tran-PK
A
phosphateKID-Ft
KID-Ft
BM3h BM3h
Fe
OH2
O
Fe
A
C
Fig. 2. Engineered metalloprotein-based MRI sensors. (A) Metalloprotein-based T1 cont
mechanism, exempliﬁed by BM3h dopamine sensors, inner sphere water molecules bo
analyte binding (right). For the BM3h-based sensors, neurotransmitter binding reduces
induces a sharp drop in the r1 of BM3h variants, from roughly 1 to 0.2 mM1 s1 for the b
The relaxivity decrease upon dopamine binding also leads to a reduction in the correspon
can be constructed by modifying protein domains in Ft to include analyte-sensitive m
constructed by genetically fusing the KID domain of the protein CREB and the KIX dom
(magenta) variants. In the presence of protien kinase A (PKA), KID domains are phosphor
and KIX-Ft proteins. (D) Kinase-dependent Ft clustering leads to a change in per-particle
KIX-Ft or from KID-Ft mixed with KIX-Ft in the presence of PKA (middle two bars) are
phosphorylation (left bar), or in the presence of the ATP phosphate source but not the kscription factor CREB, and the other with KIX domain of the protein
CBP. Upon phosphorylation of the KID domain by PKA, KID and KIX
domains interact with each other [100] and induce clustering of
KID-Ft with KIX-Ft, increasing the r2 of the sensor (Fig. 2C and
D). These sensors have not yet been applied in vivo, but may have
the potential to allow genetically targeted functional imaging of
cell or tissue types because of the all-protein nature of the Ft-based
sensors and the important role of kinases in mediating cell signal-
ing processes. Responsive Ft derivatives have also been con-
structed by chemically crosslinking Ft to reversible polymerizing
domains [101].
6. Engineering metalloproteins for high relaxivity
The chief limitation of engineered metalloproteins for targeting,
sensing, and gene reporting applications in MRI is their low relax-
ivity. For this reason, there is great interest in engineering metallo-
proteins with higher r1 and r2 than natural proteins. One approach
to this problem is to mutate metalloprotein polypeptide sequences
and examine effects on relaxivity. In one instance of this approach,
a library of P450 BM3h domains selected for neurotransmitter
afﬁnity was examined for r1 variation [24]. A range of values from
0.7 to 1.9 mM1 s1 at 4.7 T was found among mutants that dif-
fered primarily in residues near the ligand binding site proximal
to the heme. The shapes of so-called nuclear magnetic relaxation
dispersion (NMRD) curves, which plot relaxation rate as a function
of B0 ﬁeld strength, combined with X-ray crystallographic analysis,
suggested that r1 differences arose from minor variations among
multiple relaxivity determinants, with subtle changes in the me-
tal-proton distance for inner sphere water (2.6–3.0 Å) having
greatest effect on r1 (Fig. 3). Unfortunately it was not possible to
verify the inferred distance changes at the resolution of the crystal
structures, but it could be possible in the future to apply rationalH2
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Fig. 3. Nuclear magnetic relaxation dispersion of BM3h variants. (A) Mutant low spin (S = 1/2) BM3h proteins show differing T1 relaxivities as a function of magnetic ﬁeld
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mutated residues are denoted by blue balls in the protein backbone trace (gray) [126], with the heme shown in pink and the native fatty acid ligand shown in black. Color-
coded dots denote which residues are mutated with respect to the wild type protein in each of the variants listed in panel A. Mutations were selected to alter ligand binding
near the heme site and most are clustered in the ligand binding region of the protein.
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more generally indicate that non-trivial enhancement of metallo-
protein relaxivity is possible through mutagenesis and screening-
based approaches. A gain in the MRI contrast induced by human
Ft expression has also been achieved by amino-acid level changes.
Functionality of mammalian Ft is normally quite sensitive to the
balance between the Ft heavy and light chains. Iordanova et al.
fused H and L chains together and showed that the resulting chi-
mera improved relaxation rates in U2OS cells were improved by
roughly 50% [102]. Although it is unclear whether any difference
in r2 per iron or per Ft was achieved, cells harboring the construct
appeared to contain signiﬁcantly more iron than cells expressing Ft
heavy and light chains separately.
Some of the most severe limits on metalloprotein relaxivity
come from the characteristics of naturally bound metal ions them-
selves, and in particular from the spin numbers (S 6 5/2) of bound
transition metal ions. For this reason, a second strategy for creating
metalloproteins with enhanced relaxivity is to engineer the metal
content of proteins, rather than simply modifying their polypep-
tide sequences. This strategy was applied to BM3h, which normally
contains a low spin (S = 1/2) Fe3+ ion [103]. By substituting the na-
tive ferric heme with a Mn3+ protoporphyrin complex (S = 2), a gain
in relaxivity by a factor of 2.5 was obtained. In principle, the strat-
egy should have resulted in an eightfold improvement in r1, all else
being equal, suggesting that further relaxivity enhancements
might be possible by using mutagenesis approaches in parallel to
metal substitution. Non-native Mn3+ incorporation into BM3h
was made possible within bacterial cells by coexpressing BM3h
with a porphyrin transporter called ChuA. This facilitates large
scale production of metal-substituted protein in bacteria, as well
as possible applications requiring intracellular compartmentaliza-
tion of the Mn3+-containing protein variants.
Metal substitution has also been possible with Ft, which can be
engineered to contain mineral species with higher magnetization
than the natural ferrihydrite core material. The most impressive
example of this approach has been the creation of ‘‘magnetoferr-
itin,’’ an Ft complex in which magnetite is mineralized in the pro-
tein shell [104–106]. This can be accomplished by incubating
puriﬁed apoferritin under controlled pH and oxygenation condi-
tions in the presence of iron salts, and results in particles with a re-
ported r2 of 78 (mM Fe)1 s1 at 1.5 T and 37 C, comparable to
synthetic SPNs and two orders of magnitude higher than the r2of ferrihydrite-loaded Ft. Yet higher relaxivity has been reported
following mineralization of gadolinium oxide (r2 = 240 mM1 s1
at 1.5 T) [107] in Ft variants, and moderate T1 relaxivity has been
reported following mineralization of manganese oxyhydroxide
(r1 = 6 mM1 s1 at 0.47 T) [108]. This strategy has also been
adapted to convert viral capsids into protein-based MRI contrast
agents [109–111]. Finally, Ft has also been used as a compartment
for entrapment of soluble Gd-DOTA-related T1 agents [112]. This
approach takes advantage of the protein’s shell structure and avail-
ability of exchangeable protons at the protein surface, but not its
mineral nucleation capabilities per se. Very high r1 values, near
80 mM1 s1, were reported at 0.47 T. A variant of this strategy
was also used to entrap Mn2+ ions in a Ft variant engineered to con-
tain metal ions better than native Ft [113]; documented r1 and r2
values were 10 and 74 mM1s1, respectively, at 3 T. A disadvan-
tage of most metal substitution approaches for Ft and other pro-
teins is that they cannot be implemented in cells expressing a
metalloprotein, with examples like the BM3h/ChuA strategy being
occasional exceptions. Metal substituted proteins could neverthe-
less be useful contrast reagents for exogenous application in MRI
experiments, however.
A different technique for engineering metalloprotein contrast
agents is to graft metal binding functionality onto proteins or poly-
peptides that do not normally bind metals. One version of this
route was taken with the gadolinium compound MS-325, which
was designed to bind non-covalently to serum albumin in the
bloodstream [17]. The resulting complex has higher relaxivity at
B0 values because of the long sR of the albumin protein. Karfeld
et al. took a somewhat different approach by conjugating a large
number of gadolinium chelators covalently via lysine side chains
in a family of engineered repetitive polypeptides [114,115]. The
authors found that the amino acid sequence of the polypeptide
could be modiﬁed to produce substantial changes in T1 relaxivity.
A parent sequence with 22 kDa molecular weight bearing eight
Gd3+ per molecule displayed a per gadolinium r1 of 8.8 mM1 s1
at 1.4 T, but bioconjugates with denser spacing of conjugation sites
and more Gd3+ ions per polypeptide achieved r1 values up to
12.1 mM1 s1. Relaxivities of up to 14.6 mM1 s1 could also be
obtained by increasing the molecular weight of the complexes up
to 80 kD.
Polypeptide contrast agents that chelate lanthanides without
the need for bioconjugation have also been devised. In one
A B
2.5 Å 2.9 Å
5.4 Å
Fig. 4. Structures of lanthanide binding sites. (A) Structure of europium-DOTA, a
compound isomorphous to the canonical contrast agent Gd-DOTA [127]. The
structure shows coordination of the lanthanide (magenta ball) by carboxylate
oxygens and amine nitrogens on the chelator, with a single water molecule (cyan)
bound at a Eu–O distance of 2.5 Å. (B) The structure of a polypeptide lanthanide
binding tag fused to ubiquitin, in complex with gadolinium (magenta), is surprising
similar to the Eu-DOTA structure. The lanthanide is again coordinated by a mixture
of oxygen and nitrogen ligands and exhibits a q of 1, with a single inner sphere
water molecule bound at a Gd–O distance of 2.9 Å and a second sphere bound
water, which may also contribute to r1, at a distance of 5.4 Å from the lanthanide.
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multiple acidic sidechains in a cluster at the protein surface
[116]. One variant formed a Gd3+ complex with a reported r1 -
= 117 mM1 s1 at 1.5 T, and with an apparent Kd < 1 pM and
q = 2. Several efforts to construct artiﬁcial metalloprotein com-
plexes have made use of the EF hand motif [117,118], a sequence
derived from calcium binding proteins such as parvalbumin. Cara-
van et al. inserted an EF hand motif into a DNA-binding helix-loop-
helix motif to create a chimeric DNA-sensing contrast agent [119].
The Gd3+ complex has reported r1 values of 21 and 42 mM1 s1 at
1.4 T in the absence and presence of DNA, respectively. In another
study, the inherent promiscuity of metal binding by the EF hand
motif was used to generate a sensor that functions by calcium-
dependent displacement of Mn2+ ions associated with the protein
calmodulin [120]. Longitudinal relaxivity values of 11 and
8 mM1 s1 at 4.7 T were reported in the absence and presence
of 1 mM Ca2+, respectively. To improve the afﬁnity and speciﬁcity
of EF hand motifs for lanthanide binding, another group used a
luminescence assay to screen libraries of troponin-derived pep-
tides for Tb3+ binding [121,122]. T1 relaxivities were subsequently
measured from Gd3+ complexes of several variants of an optimized
peptide sequence [123]. Values of up to 5.9 mM1 s1 at 14 T were
observed, despite an apparent q = 0 for the sequence with the high-
est relaxivity. Several of the lanthanide binding tags also retained
r1 values of 2.3–5.0 mM1 s1 when fused to the small protein
ubiquitin, and crystallographic analysis of the fusion proteins re-
veals that the Gd3+-binding peptide domains are capable of form-
ing q = 1 chelate complexes similar to Gd-DOTA (Fig. 4). Although
r1 values of these domains do not exceed those of conventional
MRI contrast agents, the ability to incorporate high afﬁnity Gd3+-
binding moieties into genetically encodable proteins may facilitate
application of protein engineering techniques to further enhance
relaxivity or target analytes of interest.
7. Conclusions
The continued development and exploitation of metalloprotein
contrast agents for MRI poses unique opportunities in the ﬁelds of
molecular imaging and protein engineering. It is still uncertain
what applications protein-based MRI probes will be most success-
ful for, but utility for measuring macromolecular biokinetics and
sensing a variety of ligands in vivo seems within reach. Only metal-
loproteins that do not require chemical modiﬁcation or artiﬁcial
transmetallation are applicable as endogenously expressed report-
ers, but efforts to improve relaxivity of these agents may ulti-mately yield valuable biotechnological tools, perhaps alongside
recently-engineered diamagnetic proteins detectable by chemical
exchange saturation contrast [124]. Further analysis of structure–
activity relationships in metalloprotein contrast agents will be
interesting from a basic chemical perspective, and could also guide
design of synthetic contrast agents with enhanced properties. In
each of these contexts, the array of powerful genetic techniques
for engineering and expressing proteins will be a tremendous ben-
eﬁt, and helps make continued research in this area a potential
rewarding investment.
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